Betamimetics for suspected impaired fetal growth
Related Experiment Video
Updated: Oct 3, 2026
Fetal Echocardiography and Pulsed-wave Doppler Ultrasound in a Rabbit Model of Intrauterine Growth Restriction
Published on: June 29, 2013
1Special Department of Research, Development and Research Training in Human Reproduction, UNDP/UNFPA/WHO/World Bank, World Health Organisation, Geneva 27, Switzerland, CH-1211. gulmezoglum@who.ch
Background:
Betamimetic drugs may promote fetal growth by increasing the availability of nutrients and by decreasing vascular resistance. They may also induce adverse effects via their effects on carbohydrate metabolism.
Objectives:
The objective of this review was to assess the effects of betamimetic therapy for suspected impaired fetal growth on fetal growth and perinatal outcome.
Search Strategy:
We searched the Cochrane Pregnancy and Childbirth Group trials register and the Cochrane Controlled Trials Register. Date of the latest search: 31 May 2001.
Selection Criteria:
Randomised trials of betamimetic therapy compared with no betamimetic therapy or placebo in women with suspected impaired fetal growth.
Data Collection And Analysis:
Eligibility and trial quality was assessed.
Main Results:
Two studies of 118 women were included. No differences were found between the betamimetic groups and the control groups for low birth weight (relative risk 1.17, 95% confidence interval 0.75 to 1.83), other anthropometric measures or neonatal morbidity and mortality.
Reviewer'S Conclusions:
Larger, well-designed studies are needed to evaluate the effects of betamimetics on fetal growth. Since there is potential for adverse effects due to the pharmacological characteristics of this group of drugs, data related to any potential harms should be collected in addition to beneficial effects.
Related Concept Videos
01:07Teratogenicity
01:17Sedatives and Hypnotics Drugs: Miscellaneous Agents
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers